Base de dados : MEDLINE
Pesquisa : D20.215.894.135.685.910 [Categoria DeCS]
Referências encontradas : 1576 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 158 ir para página                         

  1 / 1576 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287062
[Au] Autor:Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
[Ad] Endereço:GSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
[Ti] Título:The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
[So] Source:PLoS One;12(12):e0189100, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In recent years there have been major efforts to develop glycoconjugate vaccines based on the Vi polysaccharide that will protect against Salmonella enterica Typhi infections, particularly typhoid fever, which remains a major public health concern in low-income countries. The design of glycoconjugate vaccines influences the immune responses they elicit. Here we systematically test the response in mice to Vi glycoconjugates that differ in Vi chain length (full-length and fragmented), carrier protein, conjugation chemistry, saccharide to protein ratio and size. We show that the length of Vi chains, but not the ultimate size of the conjugate, has an impact on the anti-Vi IgG immune response induced. Full-length Vi conjugates, independent of the carrier protein, induce peak IgG responses rapidly after just one immunization, and secondary immunization does not enhance the magnitude of these responses. Fragmented Vi linked to CRM197 and diphtheria toxoid, but not to tetanus toxoid, gives lower anti-Vi antibody responses after the first immunization than full-length Vi conjugates, but antibody titres are similar to those induced by full-length Vi conjugates following a second dose. The chemistry to conjugate Vi to the carrier protein, the linker used, and the saccharide to protein ratio do not significantly alter the response. We conclude that Vi length and carrier protein are the variables that influence the anti-Vi IgG response to immunization the most, while other parameters are of lesser importance.
[Mh] Termos MeSH primário: Glicoconjugados/imunologia
Salmonella typhi/imunologia
Vacinas Tíficas-Paratíficas/imunologia
Vacinas Conjugadas/imunologia
[Mh] Termos MeSH secundário: Animais
Proteínas de Bactérias/imunologia
Imunoglobulina G/imunologia
Camundongos
Polissacarídeos Bacterianos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Glycoconjugates); 0 (Immunoglobulin G); 0 (Polysaccharides, Bacterial); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189100


  2 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29303231
[Ti] Título:Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20­22 September 2017.
[Ti] Título:Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR-AC): résumé des conclusions et recommandations, 20-22 septembre 2017..
[So] Source:Wkly Epidemiol Rec;93(1):1-7, 2018 Jan 05.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Comitês Consultivos
Programas de Imunização/normas
Vacinas Antimaláricas/administração & dosagem
Malária/prevenção & controle
Vacinas Virais/administração & dosagem
Viroses/prevenção & controle
[Mh] Termos MeSH secundário: Fatores Etários
Mortalidade da Criança
Pré-Escolar
Cólera/epidemiologia
Cólera/prevenção & controle
Seres Humanos
Esquemas de Imunização
Lactente
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
Raiva/prevenção & controle
Vacinas Antirrábicas/administração & dosagem
Infecções por Rotavirus/prevenção & controle
Vacinas contra Rotavirus/administração & dosagem
Febre Tifoide/prevenção & controle
Vacinas Tíficas-Paratíficas/administração & dosagem
[Pt] Tipo de publicação:GUIDELINE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Malaria Vaccines); 0 (Papillomavirus Vaccines); 0 (Rabies Vaccines); 0 (Rotavirus Vaccines); 0 (Typhoid-Paratyphoid Vaccines); 0 (Viral Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE


  3 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29073137
[Au] Autor:Saha S; Islam M; Uddin MJ; Saha S; Das RC; Baqui AH; Santosham M; Black RE; Luby SP; Saha SK
[Ad] Endereço:Child Health Research Foundation, Department of Microbiology, Dhaka Shishu (Children) Hospital, Dhaka, Bangladesh.
[Ti] Título:Integration of enteric fever surveillance into the WHO-coordinated Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) platform: A low cost approach to track an increasingly important disease.
[So] Source:PLoS Negl Trop Dis;11(10):e0005999, 2017 Oct.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lack of surveillance systems and accurate data impede evidence-based decisions on treatment and prevention of enteric fever, caused by Salmonella Typhi/Paratyphi. The WHO coordinates a global Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) surveillance network but does not monitor enteric fever. We evaluated the feasibility and sustainability of integrating enteric fever surveillance into the ongoing IB-VPD platform. METHODOLOGIES: The IB-VPD surveillance system uses WHO definitions to enroll 2-59 month children hospitalized with possible pneumonia, sepsis or meningitis. We expanded this surveillance system to additionally capture suspect enteric fever cases during 2012-2016, in two WHO sentinel hospitals of Bangladesh, by adding inclusion criteria of fever ≥102°F for ≥3 days, irrespective of other manifestations. Culture-positive enteric fever cases from in-patient departments (IPD) detected in the hospital laboratories but missed by the expanded surveillance, were also enrolled to assess completion. Costs for this integration were calculated for the additional personnel and resources required. PRINCIPAL FINDINGS: In the IB-VPD surveillance, 5,185 cases were enrolled; 3% (N = 171/5185) were positive for microbiological growth, of which 55% (94/171) were culture-confirmed cases of enteric fever (85 Typhi and 9 Paratyphi A). The added inclusion criteria for enteric fever enrolled an additional 1,699 cases; 22% (358/1699) were positive, of which 85% (349/358) were enteric fever cases (305 Typhi and 44 Paratyphi A). Laboratory surveillance of in-patients of all ages enrolled 311 additional enteric fever cases (263 Typhi and 48 Paratyphi A); 9% (28/311) were 2-59 m and 91% (283/311) >59 m. Altogether, 754 (94+349+311) culture-confirmed enteric fever cases were found, of which 471 were 2-59 m. Of these 471 cases, 94% (443/471) were identified through the hospital surveillances and 6% (28/471) through laboratory results. Twenty-three percent (170/754) of all cases were children <2 years. Additional cost for the integration was USD 44,974/year, a 27% increase to the IB-VPD annual expenditure. CONCLUSION: In a setting where enteric disease is a substantial public health problem, we could integrate enteric fever surveillance into the standard IB-VPD surveillance platform at a modest cost.
[Mh] Termos MeSH primário: Vigilância em Saúde Pública/métodos
Febre Tifoide/epidemiologia
[Mh] Termos MeSH secundário: Bangladesh/epidemiologia
Pré-Escolar
Feminino
Seres Humanos
Lactente
Masculino
Febre Paratifoide/economia
Febre Paratifoide/epidemiologia
Febre Paratifoide/prevenção & controle
Salmonella paratyphi A/isolamento & purificação
Salmonella typhi/isolamento & purificação
Febre Tifoide/economia
Febre Tifoide/prevenção & controle
Vacinas Tíficas-Paratíficas/administração & dosagem
Vacinação
Organização Mundial da Saúde
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Typhoid-Paratyphoid Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171027
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005999


  4 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873442
[Au] Autor:Salerno-Gonçalves R; Tettelin H; Lou D; Steiner S; Rezwanul T; Guo Q; Picking WD; Nene V; Sztein MB
[Ad] Endereço:Center for Vaccine Development (CVD), Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States of America.
[Ti] Título:Use of a novel antigen expressing system to study the Salmonella enterica serovar Typhi protein recognition by T cells.
[So] Source:PLoS Negl Trop Dis;11(9):e0005912, 2017 Sep.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Salmonella enterica serovar Typhi (S. Typhi), the causative agent of the typhoid fever, is a pathogen of great public health importance. Typhoid vaccines have the potential to be cost-effective measures towards combating this disease, yet the antigens triggering host protective immune responses are largely unknown. Given the key role of cellular-mediated immunity in S. Typhi protection, it is crucial to identify S. Typhi proteins involved in T-cell responses. Here, cells from individuals immunized with Ty21a typhoid vaccine were collected before and after immunization and used as effectors. We also used an innovative antigen expressing system based on the infection of B-cells with recombinant Escherichia coli (E. coli) expressing one of four S. Typhi gene products (i.e., SifA, OmpC, FliC, GroEL) as targets. Using flow cytometry, we found that the pattern of response to specific S. Typhi proteins was variable. Some individuals responded to all four proteins while others responded to only one or two proteins. We next evaluated whether T-cells responding to recombinant E. coli also possess the ability to respond to purified proteins. We observed that CD4+ cell responses, but not CD8+ cell responses, to recombinant E. coli were significantly associated with the responses to purified proteins. Thus, our results demonstrate the feasibility of using an E. coli expressing system to uncover the antigen specificity of T-cells and highlight its applicability to vaccine studies. These results also emphasize the importance of selecting the stimuli appropriately when evaluating CD4+ and CD8+ cell responses.
[Mh] Termos MeSH primário: Apresentação do Antígeno
Antígenos de Bactérias/imunologia
Proteínas de Bactérias/imunologia
Polissacarídeos Bacterianos/imunologia
Salmonella typhi/imunologia
Linfócitos T/imunologia
Vacinas Tíficas-Paratíficas/imunologia
[Mh] Termos MeSH secundário: Adulto
Antígenos de Bactérias/genética
Proteínas de Bactérias/genética
Escherichia coli/genética
Escherichia coli/metabolismo
Feminino
Citometria de Fluxo
Seres Humanos
Masculino
Meia-Idade
Polissacarídeos Bacterianos/administração & dosagem
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Vacinas Tíficas-Paratíficas/administração & dosagem
Voluntários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Bacterial Proteins); 0 (Polysaccharides, Bacterial); 0 (Recombinant Proteins); 0 (Ty21a typhoid vaccine); 0 (Typhoid-Paratyphoid Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005912


  5 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28735760
[Au] Autor:Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
[Ad] Endereço:Vaccine Program, Human Health Therapeutics Portfolio, National Research Council, Ottawa, Canada; Health Biotechnology Division, National Institute for Biotechnology, Faisalabad, Pakistan; Department of Microbiology and Biotechnology, Abasyn University, Peshawar, Pakistan. Electronic address: s.amaza
[Ti] Título:First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
[So] Source:J Immunol Methods;450:27-33, 2017 Nov.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Efficacious typhoid vaccines for young children will significantly reduce the disease burden in developing world. The Vi polysaccharide based conjugate vaccines (Vi-rEPA) against Salmonella Typhi Vi positive strains has shown high efficacy but may be ineffective against Vi negative S. Typhi. In this study, for the first time, we report the synthesis and evaluation of polysaccharide-protein conjugates of Vi negative S. Typhi as potential vaccine candidates. Four different conjugates were synthesized using recombinant exoprotein A of Pseudomonas aeruginosa (rEPA) and human serum albumin (HSA) as the carrier proteins, using either direct reductive amination or an intermediate linker molecule, adipic acid dihydrazide (ADH). Upon injection into mice, a significantly higher antibody titer was observed in mice administrated with conjugate-1 (OSP-HSA) (P=0.0001) and conjugate 2 (OSP-rEPA) (P≤0.0001) as compared to OSP alone. In contrast, the antibody titer elicited by conjugate 3 (OSP -HSA) and conjugate 4 (OSP -rEPA) were insignificant (P=0.1684 and P=0.3794, respectively). We conclude that reductive amination is the superior method to prepare the S. Typhi OSP glycoconjugate. Moreover, rEPA was a better carrier protein than HSA. Thus OSP-rEPA conjugate seems to be efficacious typhoid vaccines candidate, it may be evaluated further and recommended for the clinical trials.
[Mh] Termos MeSH primário: ADP Ribose Transferases/imunologia
Toxinas Bacterianas/imunologia
Exotoxinas/imunologia
Antígenos O/imunologia
Polissacarídeos Bacterianos/imunologia
Salmonella typhi/imunologia
Vacinas Tíficas-Paratíficas/imunologia
Fatores de Virulência/imunologia
[Mh] Termos MeSH secundário: ADP Ribose Transferases/administração & dosagem
ADP Ribose Transferases/química
Aminação
Animais
Anticorpos Antibacterianos/sangue
Toxinas Bacterianas/administração & dosagem
Toxinas Bacterianas/química
Western Blotting
Eletroforese em Gel de Poliacrilamida
Exotoxinas/administração & dosagem
Exotoxinas/química
Feminino
Imunização
Esquemas de Imunização
Injeções Intraperitoneais
Camundongos Endogâmicos BALB C
Antígenos O/administração & dosagem
Antígenos O/química
Oxirredução
Espectroscopia de Prótons por Ressonância Magnética
Proteínas Recombinantes/imunologia
Albumina Sérica/imunologia
Albumina Sérica Humana
Vacinas Tíficas-Paratíficas/administração & dosagem
Vacinas Tíficas-Paratíficas/química
Vacinas Conjugadas/imunologia
Fatores de Virulência/administração & dosagem
Fatores de Virulência/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ALB protein, human); 0 (Antibodies, Bacterial); 0 (Bacterial Toxins); 0 (Exotoxins); 0 (O Antigens); 0 (Polysaccharides, Bacterial); 0 (Recombinant Proteins); 0 (Serum Albumin); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vaccines, Conjugate); 0 (Virulence Factors); 0 (capsular polysaccharide, Salmonella); EC 2.4.2.- (ADP Ribose Transferases); EC 2.4.2.31 (toxA protein, Pseudomonas aeruginosa); ZIF514RVZR (Serum Albumin, Human)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170725
[St] Status:MEDLINE


  6 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28675263
[Au] Autor:Pakkanen SH; Kantele JM; Rombo L; Kantele A
[Ad] Endereço:Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
[Ti] Título:Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
[So] Source:Scand J Immunol;86(4):207-215, 2017 Oct.
[Is] ISSN:1365-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Secondary immunization with polysaccharide vaccines may imply a risk of hyporesponsiveness. Despite the wide use of typhoid Vi capsular polysaccharide vaccine, its potential tendency to hyporesponsiveness has been inadequately addressed. While previous studies have explored serum antibody responses, we applied a more sensitive approach, a single-cell assay for circulating plasmablasts, to compare primary and secondary responses. Twelve subjects received primary and booster doses of the Vi vaccine (Typherix ) at 30- to 37-month intervals. Plasmablasts specific to the Vi or typhoidal O antigens or cross-reactive with paratyphoid and non-typhoidal Salmonella strains were identified as antibody-secreting cells (ASC) with ELISPOT. Before vaccinations, none had plasmablasts specific to the antigens tested. Twelve of 12 subjects showed a Vi-specific response after primary, but only eight of 12 after booster vaccination. All responded to typhoidal O-9,12 antigen after both immunizations. The geometric mean of plasmablasts specific to the Vi antigen was 59 (95% CI 24-119) and 1 (0-54) IgA + IgG + IgM-ASC/10 peripheral blood mononuclear cell (PBMC) after primary and booster immunizations, respectively, and 20 (9-49) and 56 (29-103) to the O-9,12 antigen. We detected 1 (0-28) and 17 (6-36) ASC/10 PBMC cross-reactive with Salmonella Paratyphi A; 3 (0-30) and 22 (8-48) with S. Paratyphi B; 3 (0-29) and 18 (7-47) with S. Paratyphi C; 19 (10-34) and 51 (26-94) with Salmonella Enteritidis; and 1 (0-35) and 23 (9-52) with Salmonella Typhimurium, respectively. One-third of the vaccinees, although responding to the O-9,12 antigen, failed to respond to the Vi antigen after booster immunization, suggesting hyporesponsiveness in part of the vaccinees. The findings warrant further investigation.
[Mh] Termos MeSH primário: Epitopos/imunologia
Leucócitos Mononucleares/imunologia
Plasmócitos/imunologia
Polissacarídeos Bacterianos/imunologia
Salmonella typhi/imunologia
Febre Tifoide/imunologia
Vacinas Tíficas-Paratíficas/imunologia
[Mh] Termos MeSH secundário: Adulto
Células Cultivadas
Reações Cruzadas
ELISPOT
Feminino
Seres Humanos
Imunização Secundária
Masculino
Meia-Idade
Antígenos O/imunologia
Análise de Célula Única
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Epitopes); 0 (O Antigens); 0 (Polysaccharides, Bacterial); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vi polysaccharide vaccine, typhoid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1111/sji.12583


  7 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28625884
[Au] Autor:Ferlito C; Barnaba V; Abrignani S; Bombaci M; Sette A; Sidney J; Biselli R; Tomao E; Cattaruzza MS; Germano V; Biondo MI; Salerno G; Lulli P; Caporuscio S; Picchianti Diamanti A; Falco M; Biselli V; Cardelli P; Autore A; Lucertini E; De Cesare DP; Peragallo MS; Lista F; Martire C; Salemi S; Nisini R; D'Amelio R
[Ad] Endereço:Sapienza Università di Roma, Dipartimento di Medicina Clinica e Molecolare Azienda Ospedaliera S. Andrea, Roma, Italy.
[Ti] Título:Lack of evidence for post-vaccine onset of autoimmune/lymphoproliferative disorders, during a nine-month follow-up in multiply vaccinated Italian military personnel.
[So] Source:Clin Immunol;181:60-66, 2017 Aug.
[Is] ISSN:1521-7035
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anecdotal case reports, amplified by mass media and internet-based opinion groups, have recently indicated vaccinations as possibly responsible for autoimmunity/lymphoproliferation development. Multiply vaccinated Italian military personnel (group 1, operating in Italy, group 2, operating in Lebanon) were followed-up for nine months to monitor possible post-vaccine autoimmunity/lymphoproliferation onset. No serious adverse event was noticed in both groups. Multivariate analysis of intergroup differences only showed a significant association between lymphocyte increase and tetanus/diphtheria vaccine administration. A significant post-vaccine decrease in autoantibody positivity was observed. Autoantibodies were also studied by microarray analysis of self-proteins in subjects exposed to ≥4 concurrent vaccinations, without observing significant difference among baseline and one and nine months post-vaccine. Moreover, HLA-A2 subjects have been analyzed for the possible CD8T-cell response to apoptotic self-epitopes, without observing significant difference between baseline and one month post-vaccine. Multiple vaccinations in young adults are safe and not associated to autoimmunity/lymphoproliferation onset during a nine-month-long follow-up.
[Mh] Termos MeSH primário: Doenças Autoimunes/epidemiologia
Transtornos Linfoproliferativos/epidemiologia
Militares/estatística & dados numéricos
Vacinas/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anticorpos Anticitoplasma de Neutrófilos/imunologia
Anticorpos Antinucleares/imunologia
Anticorpos Antifosfolipídeos/imunologia
Autoanticorpos/imunologia
Doenças Autoimunes/imunologia
Eletroforese das Proteínas Sanguíneas
Vacina contra Varicela/uso terapêutico
Vacina contra Difteria e Tétano/uso terapêutico
Feminino
Seguimentos
Vacinas contra Hepatite A/uso terapêutico
Vacinas contra Hepatite B/uso terapêutico
Seres Humanos
Imunoglobulinas/sangue
Vacinas contra Influenza/uso terapêutico
Itália/epidemiologia
Transtornos Linfoproliferativos/imunologia
Masculino
Vacina contra Sarampo-Caxumba-Rubéola/uso terapêutico
Vacinas Meningocócicas/uso terapêutico
Vacina Antipólio de Vírus Inativado/uso terapêutico
Estudos Prospectivos
Fator Reumatoide/imunologia
Fatores de Risco
Vacinas Tíficas-Paratíficas/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Antibodies, Antinuclear); 0 (Antibodies, Antiphospholipid); 0 (Autoantibodies); 0 (Chickenpox Vaccine); 0 (Diphtheria-Tetanus Vaccine); 0 (Hepatitis A Vaccines); 0 (Hepatitis B Vaccines); 0 (Immunoglobulins); 0 (Influenza Vaccines); 0 (Measles-Mumps-Rubella Vaccine); 0 (Meningococcal Vaccines); 0 (Poliovirus Vaccine, Inactivated); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vaccines); 0 (anti-extractable nuclear antigen antibodies); 9009-79-4 (Rheumatoid Factor)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE


  8 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28545919
[Au] Autor:Prabagaran SR; Kalaiselvi V; Chandramouleeswaran N; Deepthi KNG; Brahmadathan KN; Mani M
[Ad] Endereço:Department of Biotechnology, Bharathiar University, Coimbatore, Tamilnadu 641 046, India. Electronic address: prabagaran@buc.edu.in.
[Ti] Título:Molecular diagnosis of Salmonella typhi and its virulence in suspected typhoid blood samples through nested multiplex PCR.
[So] Source:J Microbiol Methods;139:150-154, 2017 Aug.
[Is] ISSN:1872-8359
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A nested multiplex polymerase chain reaction (PCR) based diagnosis was developed for the detection of virulent Salmonella typhi in the blood specimens from patients suspected for typhoid fever. After the Widal test, two pairs of primers were used for the detection of flagellin gene (fliC) of S. typhi. Among them, those positive for fliC alone were subjected to identification of genes in Via B operon of Salmonella Pathogenesity Island (SPI-7) where four primer pairs were used to detect tviA and tviB genes. Among 250 blood samples tested, 115 were positive by fliC PCR; 22 of these were negative for tviA and tviB. Hence, the method described here can be used to diagnose the incidence of Vi-negative serovar typhi especially in endemic regions where the Vi vaccine is administered.
[Mh] Termos MeSH primário: Sangue/microbiologia
Reação em Cadeia da Polimerase Multiplex/métodos
Salmonella typhi/isolamento & purificação
Salmonella typhi/patogenicidade
Febre Tifoide/diagnóstico
[Mh] Termos MeSH secundário: Proteínas de Bactérias/genética
Primers do DNA
DNA Bacteriano/sangue
Feminino
Flagelina/genética
Ilhas Genômicas/genética
Seres Humanos
Masculino
Técnicas de Diagnóstico Molecular/métodos
Óperon
Salmonella typhi/genética
Sensibilidade e Especificidade
Fatores de Transcrição/genética
Febre Tifoide/microbiologia
Vacinas Tíficas-Paratíficas
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (DNA Primers); 0 (DNA, Bacterial); 0 (Transcription Factors); 0 (Typhoid-Paratyphoid Vaccines); 0 (tviA protein, Salmonella typhi); 12777-81-0 (Flagellin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170527
[St] Status:MEDLINE


  9 / 1576 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28544285
[Au] Autor:Yap KP; Thong KL
[Ad] Endereço:Institute of Biological Science, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
[Ti] Título:Salmonella Typhi genomics: envisaging the future of typhoid eradication.
[So] Source:Trop Med Int Health;22(8):918-925, 2017 Aug.
[Is] ISSN:1365-3156
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Next-generation whole-genome sequencing has revolutionised the study of infectious diseases in recent years. The availability of genome sequences and its understanding have transformed the field of molecular microbiology, epidemiology, infection treatments and vaccine developments. We review the key findings of the publicly accessible genomes of Salmonella enterica serovar Typhi since the first complete genome to the most recent release of thousands of Salmonella Typhi genomes, which remarkably shape the genomic research of S. Typhi and other pathogens. Important new insights acquired from the genome sequencing of S. Typhi, pertaining to genomic variations, evolution, population structure, antibiotic resistance, virulence, pathogenesis, disease surveillance/investigation and disease control are discussed. As the numbers of sequenced genomes are increasing at an unprecedented rate, fine variations in the gene pool of S. Typhi are captured in high resolution, allowing deeper understanding of the pathogen's evolutionary trends and its pathogenesis, paving the way to bringing us closer to eradication of typhoid through effective vaccine/treatment development.
[Mh] Termos MeSH primário: Resistência Microbiana a Medicamentos
Genoma Bacteriano
Salmonella typhi/genética
Febre Tifoide/microbiologia
Vacinas Tíficas-Paratíficas
[Mh] Termos MeSH secundário: Evolução Biológica
Seres Humanos
Filogenia
Salmonella typhi/patogenicidade
Febre Tifoide/tratamento farmacológico
Febre Tifoide/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Typhoid-Paratyphoid Vaccines)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1111/tmi.12899


  10 / 1576 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28413874
[Ti] Título:Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1­2 February 2017 meeting.
[Ti] Título:Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR AC): résumé des conclusions et recommandations, reunion du 1er et 2 février 2017..
[So] Source:Wkly Epidemiol Rec;92(15):181-8, 2017 04 14.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Comitês Consultivos
Pesquisa Biomédica
Vacinas
Organização Mundial da Saúde
[Mh] Termos MeSH secundário: Vacinas contra Dengue
Hepatite B/epidemiologia
Hepatite B/imunologia
Antígenos de Superfície da Hepatite B/sangue
Seres Humanos
Vacinas contra Influenza/administração & dosagem
Licenciamento
Sarampo/mortalidade
Estudos Observacionais como Assunto
Estudos Soroepidemiológicos
Febre Tifoide/prevenção & controle
Vacinas Tíficas-Paratíficas/administração & dosagem
Vacinas Tíficas-Paratíficas/imunologia
Vacinas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Dengue Vaccines); 0 (Hepatitis B Surface Antigens); 0 (Influenza Vaccines); 0 (Typhoid-Paratyphoid Vaccines); 0 (Vaccines)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE



página 1 de 158 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde